bullish stock, +45% in 2017, doubled since nov., recently agreed to a settlement in lawsuit where vrx paid 96.25m and pershing square paid 193.75m(33% and 66% respectively). This settlement is the cause for the recent pullback. looking to break res level soon. fundamentally sound since new CEO has taken control. new fda approval for acne drug = bullish